Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses

Oral Oncology

Volumn 45, Issue 12, 2009, Pages 1021-1027

  Saito, Kengo ^a   Shirasawa, Hiroshi ^a   Isegawa, Naohisa ^a   Shiiba, Masashi ^a   Uzawa, Katsuhiro ^a   Tanzawa, Hideki ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Oncolytic virotherapy; Oncolytic virus; Oral; Squamous cell carcinoma

Indexed keywords

ACICLOVIR; ADVEXIN; CISPLATIN; FLUOROURACIL; GANCICLOVIR; H 101; HF 10; HSV 1716; ONCOLYTIC VIRUS; ONCOVEX; ONCOVEX GM CSF; ONYX 015; PV 701; SIN AR 339; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CHILL; CLINICAL TRIAL; COLORECTAL TUMOR; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; ESOPHAGUS CARCINOMA; FEVER; FLU LIKE SYNDROME; GENETIC ENGINEERING; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK TUMOR; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INFLAMMATION; INJECTION SITE PAIN; MEASLES VIRUS; MOUTH CARCINOMA; MOUTH DISEASE; MOUTH PAIN; NAUSEA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; ORAL DYSPLASIA; ORAL EPITHELIAL DYSPLASIA; ORAL SQUAMOUS CELL CARCINOMA; OVARY TUMOR; PANCREAS TUMOR; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REOVIRUS; REVIEW; SEMLIKI FOREST ALPHAVIRUS; SINDBIS VIRUS; SQUAMOUS CELL CARCINOMA; STOMATITIS; TUMOR; TUMOR CELL; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VESICULAR STOMATITIS VIRUS; VIRULENCE; VIRUS REPLICATION; VOMITING;

ADENOVIRIDAE; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; HERPESVIRUS 1, HUMAN; HUMANS; MOUTH NEOPLASMS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; SINDBIS VIRUS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 70449522973     PISSN: 13688375     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2009.09.002     Document Type: Review

References (95)

1. Casiglia J., and Woo S.B. A comprehensive review of oral cancer. Gen Dent 49 1 (2001) 72-82
2. Tankere F., Camproux A., Barry B., Guedon C., Depondt J., and Gehanno P. Prognostic value of lymph node involvement in oral cancers: a study of 137 cases. Laryngoscope 110 12 (2000) 2061-2065
3. Jemal A., Murray T., Samuels A., Ghafoor A., Ward E., and Thun M.J. Cancer statistics 2003. CA Cancer J Clin 53 1 (2003) 5-26
4. Xi S., and Grandis J.R. Gene therapy for the treatment of oral squamous cell carcinoma. J Dent Res 82 1 (2003) 11-16
5. Kim E.S., Kies M., and Herbst R.S. Novel therapeutics for head and neck cancer. Curr Opin Oncol 14 3 (2002) 334-342
6. Wakasa T., Inoue T., Kawai N., Murakami J., Kishi K., and Fukui K. The combination of ionizing radiation and expression of a wild type p53 gene via recombinant adenovirus induced a prominent tumour suppressing effect in human oral squamous cell carcinoma. Br J Radiol 75 896 (2002) 657-662
7. Schrijvers D., Johnson J., Jiminez U., Gore M., Kosmidis P., Szpirglas H., et al. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. J Clin Oncol 16 3 (1998) 1054-1059
8. Saraswathi T.R., Kavitha B., and Vijayashree Priyadharsini J. Gene therapy for oral squamous cell carcinoma: an overview. Indian J Dent Res 18 3 (2007) 120-123
9. Kirn D.H., and Thorne S.H. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 9 1 (2009) 64-71
10. Kerr D. Clinical development of gene therapy for colorectal cancer. Nature Rev Cancer 3 8 (2003) 615-622
11. Zeimet A.G., and Marth C. Why did p53 gene therapy fail in ovarian cancer?. Lancet Oncol 4 7 (2003) 415-422
12. McCormick F. Cancer gene therapy: fringe or cutting edge?. Nature Rev Cancer 1 2 (2001) 130-141
13. Farassati F., Yang A.D., and Lee P.W. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat Cell Biol 3 8 (2001) 745-750
14. Imperiale M.J., Kao H.T., Feldman L.T., Nevins J.R., and Strickland S. Common control of the heat-shock gene and early adenovirus genes - evidence for a cellular E1A-like activity. Mol Cell Biol 4 5 (1984) 867-874
15. Working P.K., Lin A., and Borellini F. Meeting product development challenges in manufacturing clinical grade oncolytic adenoviruses. Oncogene 24 52 (2005) 7792-7801
16. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., and Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 3 6 (1997) 639-645
17. Bell J.C., Lichty B., and Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 4 1 (2003) 7-11
18. Parato K.A., Senger D., Forsyth P.A., and Bell J.C. Recent progress in the battle between oncolytic viruses and tumours. Nature Rev Cancer 5 12 (2005) 965-976
19. Thorne S.H., Hermiston T., and Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 32 6 (2005) 537-548
20. Coffey M.C., Strong J.E., Forsyth P.A., and Lee P.W. Reovirus therapy of tumors with activated Ras pathway. Science 282 5392 (1998) 1332-1334
21. Norman K.L., and Lee P.W. Reovirus as a novel oncolytic agent. J Clin Invest 105 8 (2000) 1035-1038
22. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nature Med 6 7 (2000) 821-825
23. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4 4 (2003) 263-275
24. Bischoff J.R., Kirn D.H., Williams A., Heise C., Horn S., Muna M., et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274 5286 (1996) 373-376
25. Heise C., Hermiston T., Johnson L., Brooks G., Sampson-Johannes A., Williams A., et al. An adenovirus E1A mutant that demonstrates potent and selective antitumoral efficacy. Nature Med 6 10 (2000) 1134-1139
26. Mineta T., Rabkin S.D., Yazaki T., Hunter W.D., and Martuza R.L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med 1 9 (1995) 938-943
27. Mineta T., Rabkin S.D., and Martuza R.L. Treatment of malignant gliomas using ganciclovir-hypersensitive ribonucleotide reductase-deficient herpes simplex viral mutant. Cancer Res 54 15 (1994) 3963-3966
28. Comins C., Heinemann L., Harrington K., Melcher A., De Bono J., and Pandha H. Reovirus: viral therapy for cancer 'as nature intended'. Clin Oncol 20 7 (2008) 548-554
29. Kirn D., Hermiston T., and McCormick F. ONYX-015: clinical data are encouraging. Nature Med 4 12 (1998) 1341-1342
30. Khuri F.R., Nemunaitis J., Ganly I., Arseneau J., Tannock I.F., Romel L., et al. A controlled trial of intratumoral Onyx-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluororacil in patients with recurrent head and neck cancer. Nature Med 6 8 (2000) 879-885
31. Nemunaitis J., Khuri F., Ganly I., Arseneau J., Posner M., Vokes E., et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 19 2 (2001) 289-298
32. Reid T., Galanis E., Abbruzzese J., Sze D., Andrews J., Romel L., et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8 21 (2001) 1618-1626
33. Reid T., Galanis E., Abbruzzese J., Sze D., Wein L.M., Andrews J., et al. Hepatic arterial infusion of a replication selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62 21 (2002) 6070-6079
34. Liu T.C., Hwang T.H., Bell J.C., and Kirn D.H. Translation of targeted oncolytic virotherapeutics from the lab into the clinic, and back again: a high-value iterative loop. Mol Ther 16 6 (2008) 1006-1008
35. Liu T.C., and Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 67 2 (2007) 429-432
36. Chiocca E.A. Oncolytic viruses. Nat Rev Cancer 2 12 (2002) 938-950
37. Everts B., and van der Poel H.G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 12 4 (2005) 141-161
38. Ring C.J. Cytolytic viruses as potential anti-cancer agents. J Gen Virol 83 (2002) 491-502
39. Ward T.G., Huebner R.J., Rowe W.P., Ryan R.W., and Bell J.A. Production of pharyngoconjunctival fever in human volunteers inoculated with APC viruses. Science 122 3179 (1995) 1086-1087
40. Mitsui Y., Hanabusa J., Minoda R., and Ogata S. Effect of inoculating adenovirus (APC virus) type 8 into human volunteers. Am J Ophthalmol 43 (1957) 84-90
41. Huneycutt B.S., Bi Z., Aoki C.J., and Reiss C.S. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol 67 11 (1993) 6698-6706
42. Stojdl D.F., Abraham N., Knowles S., Marius R., Brasey A., Lichty B.D., et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J Virol 74 20 (2000) 580-585
43. Southam C.M. Present status of oncolytic virus studies. Trans NY Acad Sci 22 (1960) 656-673
44. Chu R.L., Post D.E., Khuri F.R., and Van Meir E.G. Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10 16 (2004) 5299-5312
45. Martuza R.L. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 105 7 (2000) 841-846
46. Roizman B. The function of herpes simplex virus genes: a primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 93 21 (1996) 11307-11312
47. Chou J., Kern E.R., Whitley R.J., and Roizman B. Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250 4985 (1990) 1262-1266
48. Chun Y.S., Adusumilli P.S., and Fong Y. Employing tumor hypoxia for oncolytic therapy in breast cancer. J Mammary Gland Biol Neoplasia 10 4 (2005) 311-318
49. Russell S.J., and Peng K.W. Viruses as anticancer drugs. Trends Pharmacol Sci 28 7 (2007) 326-333
50. Nemunaitis J., Cunningham C., Buchanan A., Blackburn A., Edelman G., Maples P., et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8 10 (2001) 746-759
51. Kirn D., Martuza R.L., and Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7 7 (2001) 781-787
52. Kirn D. Replication-selective oncolytic adenoviruses: virotherapy aimed at genetic targets in cancer. Oncogene 19 56 (2000) 6660-6668
53. Xia Z.J., Chang J.H., Zhang L., Jiang W.Q., Guan Z.Z., Liu J.W., et al. Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23 12 (2004) 1666-1670
54. Russell S.J. Replicating vectors for cancer therapy: a question of strategy. Semin Cancer Biol 5 6 (1994) 437-443
55. Russell S.J. Replicating vectors for gene therapy of cancer: risks, limitations and prospects. Eur J Cancer 30A 8 (1994) 1165-1171
56. McCormick F. Future prospects for oncolytic therapy. Oncogene 24 52 (2005) 7817-7819
57. Vähä-Koskela M.J., Heikkilä J.E., and Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett 254 2 (2007) 178-216
58. Aghi M., and Martuza R.L. Oncolytic viral therapies: the clinical experience. Oncogene 24 52 (2005) 7802-7816
59. Ganly I., Kirn D., Eckhardt G., Rodriguez G.I., Soutar D.S., Otto R., et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6 3 (2000) 798-806
60. Advani S.J., Mezhir J.J., Roizman B., and Weichselbaum R.R. ReVOLT: radiation-enhanced viral oncolytic therapy. Int J Radiat Oncol Biol Phys 66 3 (2006) 637-646
61. Yotnda P., Chen D.H., Chiu W., Piedra P.A., Davis A., Templeton N.S., et al. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol Ther 5 3 (2002) 233-241
62. Croyle M.A., Chirmule N., Zhang Y., and Wilson J.M. ''Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75 10 (2001) 4792-4801
63. O'Riordan C.R., Lachapelle A., Delgado C., Parkes V., Wadsworth S.C., Smith A.E., et al. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10 8 (1999) 1349-1358
64. Siemens D.R., Elzey B.D., Lubaroff D.M., Bohlken C., Jensen R.J., Swanson A.K., et al. Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol 166 2 (2001) 731-735
65. Nemunaitis J., Ganly I., Khuri F., Arseneau J., Kuhn J., McCarty T., et al. Selective replication and oncolysis in p53 mutant tumors with Onyx-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res 60 22 (2000) 6359-6366
66. Herrlinger U., Kramm C.M., Aboody-Guterman K.S., Silver J.S., Ikeda K., Johnston K.M., et al. Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther 5 6 (1998) 809-819
67. Neff-LaFord H.D., Vorderstrasse B.A., and Lawrence B.P. Fewer CTL, not enhanced NK cells, are sufficient for viral clearance from the lungs of immunocompromised mice. Cell Immunol 226 1 (2003) 54-64
68. Snow G.B. Evaluation and staging of the patient with head and neck cancer (1989), New York, Churchill Livingstone, Inc. p. 17-38
69. Ahomadegbe J.C., Barrois M., Fogel S., Le Bihan M.L., Douc-Rasy S., Duvillard P., et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumours and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 10 6 (1995) 1217-1227
70. Boyle J.O., Hakim J., Koch W., van der Riet P., Hruban R.H., Roa R.A., et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53 19 (1993) 4477-4480
71. Shin D.M., Kim J., Ro J.Y., Hittelman J., Roth J.A., Hong W.K., et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 54 2 (1994) 321-326
72. Rudin C.M., Cohen E.E., Papadimitrakopoulou V.A., Silverman Jr. S., Recant W., El-Naggar A.K., et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21 24 (2003) 4546-4552
73. Brown S.M., Harland J., MacLean A.R., Podlech J., and Clements J.B. Cell type and cell state determine differential in vitro growth of non-neurovirulent ICP34.5-negative herpes simplex virus types 1 and 2. J Gen Virol 75 (1994) 2367-2377
74. Lasner T.M., Kesari S., Brown S.M., Lee V.M., Fraser N.W., and Trojanowski J.Q. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 55 12 (1996) 1259-1269
75. Randazzo B.P., Kesari S., Gesser R.M., Alsop D., Ford J.C., Brown S.M., et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211 1 (1995) 94-101
76. Randazzo B.P., Bhat M.G., Kesari S., Fraser N.W., and Brown S.M. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J Invest Dermatol 108 6 (1997) 933-937
77. Kesari S., Randazzo B.P., Valyi-Nagy T., Huang Q.S., Brown S.M., MacLean A.R., et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab Invest 73 5 (1995) 636-648
78. Kucharczuk J.C., Randazzo B., Chang M.Y., Amin K.M., Elshami A.A., Sterman D.H., et al. Use of a ''replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 57 3 (1997) 466-471
79. Toyoizumi T., Mick R., Abbas A.E., Kang E.H., Kaiser L.R., and Molnar-Kimber K.L. Combined therapy with chemotherapeutic agents and herpes simplex virus type 1 ICP34.5 mutant (HSV-1716) in human non-small cell lung cancer. Hum Gene Ther 10 18 (1999) 3013-3029
80. Mace A.T., Harrow S.J., Ganly I., and Brown S.M. Cytotoxic effects of the oncolytic herpes simplex virus HSV1716 alone and in combination with cisplatin in head and neck squamous cell carcinoma. Acta Otolaryngol 127 8 (2007) 880-887
81. Mace A.T., Ganly I., Soutar D.S., and Brown S.M. Potential for efficacy of the oncolytic Herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 30 8 (2008) 1045-1051
82. GM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12 22 (2006) 6737-6747
83. Pecora A.L., Rizvi N., Cohen G.I., Meropol N.J., Sterman D., Marshall J.L., et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20 9 (2002) 2251-2266
84. Griffin DE. Alphaviruses. In: Knipe DM, Howley PM, editors. Fields virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins, 2001. p. 917-962.
85. Tseng J.C., Levin B., Hirano T., Yee H., Pampeno C., and Meruelo D. In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst 94 23 (2002) 1790-1802
86. Wang K.S., Kuhn R.J., Strauss E.G., Ou S., and Strauss J.H. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 66 8 (1992) 4992-5001
87. van den Brûle F.A., Castronovo V., Ménard S., Giavazzi R., Marzola M., Belotti D., et al. Expression of the 67 kD laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. Eur J Cancer 32A 9 (1996) 1598-1602
88. Al-Saleh W., Delvenne P., van den Brule F.A., Menard S., Boniver J., and Castronovo V. Expression of the 67 KD laminin receptor in human cervical preneoplastic and neoplastic squamous epithelial lesions: an immunohistochemical study. J Pathol 181 3 (1997) 287-293
89. Unno Y., Shino Y., Kondo F., Igarashi N., Wang G., Shimura R., et al. Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin Cancer Res 11 12 (2005) 4553-4560
90. Lundstrom K. Alphavirus vectors for gene therapy applications. Curr Gene Ther 1 1 (2001) 19-29
91. Liljeström P., and Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. BioTechnology 9 12 (1991) 1356-1361
92. Xiong C., Levis R., Shen P., Schlesinger S., Rice C.M., and Huang H.V. Sindbis virus: an efficient broad host range vector for gene expression in animal cells. Science 243 4895 (1989) 1188-1191
93. Davis N.L., Willis L.V., Smith J.F., and Johnston R.E. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 171 1 (1989) 189-204
94. Lundstrom K. Latest development in viral vectors for gene therapy. Trends Biotechnol 21 3 (2003) 117-122
95. Fujimoto Y., Mizuno T., Sugiura S., Goshima F., Kohno S., Nakashima T., et al. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma. Acta Otolaryngol 126 10 (2006) 1115-1117